[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636783":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":65,"centralContacts":69,"locations":75,"responsibleParty":300,"collaborators":37,"id":302,"slug":303,"hasResults":304,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":37,"eligibilityCriteria":308,"healthyVolunteers":304,"sex":309,"minAge":310,"maxAge":37,"enrollmentInfo":311,"targetDuration":37,"studyType":314,"phases":315,"briefSummary":318,"conditions":319,"keywords":37,"overallStatus":78,"whyStopped":37,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":330},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,21,25],{"label":9,"type":10,"description":11,"interventionNames":12},"MK-1045 Dose Regimen A","EXPERIMENTAL","Participants will receive a lower MK-1045 dose once weekly for up to 13 cycles (two 28-day and eleven 42-day cycles). Participants will have the option to change treatment at the end of Part 1.",[13,14,15,16,17,18,19,20],"Biological: MK-1045","Drug: Acetaminophen","Drug: Diphenhydramine","Drug: Dexamethasone","Drug: Tocilizumab","Drug: Siltuximab","Drug: Avtozma","Drug: Tyenne",{"label":22,"type":10,"description":23,"interventionNames":24},"MK-1045 Dose Regimen B","Participants will receive a larger MK-1045 dose once weekly for up to 13 cycles (two 28-day and eleven 42-day cycles). Participants will have the option to change treatment at the end of Part 1.",[13,14,15,16,17,18,19,20],{"label":26,"type":27,"description":28,"interventionNames":29},"Blinatumomab","ACTIVE_COMPARATOR","Participants will receive blinatumomab on days 1, 8, 15, and 22 of each 42-day cycle",[30,16,17,18,19,20],"Biological: Blinatumomab",[32,38,40,45,49,52,56,59,62],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"BIOLOGICAL","MK-1045","Intravenous administration",[9,22],null,{"type":33,"name":26,"description":35,"armGroupLabels":39,"otherNames":37},[26],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":37},"DRUG","Acetaminophen","Oral administration as a premedication",[9,22],{"type":41,"name":46,"description":47,"armGroupLabels":48,"otherNames":37},"Diphenhydramine","Intravenous administration as a premedication",[9,22],{"type":41,"name":50,"description":47,"armGroupLabels":51,"otherNames":37},"Dexamethasone",[26,9,22],{"type":41,"name":53,"description":54,"armGroupLabels":55,"otherNames":37},"Tocilizumab","Intravenous administration as a rescue medication",[26,9,22],{"type":41,"name":57,"description":54,"armGroupLabels":58,"otherNames":37},"Siltuximab",[26,9,22],{"type":41,"name":60,"description":54,"armGroupLabels":61,"otherNames":37},"Avtozma",[26,9,22],{"type":41,"name":63,"description":54,"armGroupLabels":64,"otherNames":37},"Tyenne",[26,9,22],[66],{"name":67,"affiliation":5,"role":68},"Medical Director","STUDY_DIRECTOR",[70],{"name":71,"role":72,"phone":73,"phoneExt":37,"email":74},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[76,94,102,115,130,139,151,165,177,189,201,216,226,238,248,261,276,288],{"facility":77,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"Rigshospitalet ( Site 0802)","RECRUITING","Copenhagen","Capital Region","2100","Denmark","DK",{"type":85,"coordinates":86},"Point",[87,88],12.56553,55.67594,{"lat":88,"lon":87},[91],{"name":92,"role":72,"phone":93,"phoneExt":37,"email":37},"Study Coordinator","+45 35455375",{"facility":95,"status":78,"city":96,"state":97,"zip":98,"country":82,"countryCode":83,"cosmosGeoPoint":37,"geoPoint":37,"contacts":99},"Aarhus Universitetshospital. Hæmatologisk afdeling ( Site 0804)","Aarhus Nord","Central Jutland","8200",[100],{"name":92,"role":72,"phone":101,"phoneExt":37,"email":37},"+4578450000",{"facility":103,"status":78,"city":104,"state":105,"zip":106,"country":82,"countryCode":83,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"Odense Universitetshospital ( Site 0801)","Odense","Region Syddanmark","5000",{"type":85,"coordinates":108},[109,110],10.38831,55.39594,{"lat":110,"lon":109},[113],{"name":92,"role":72,"phone":114,"phoneExt":37,"email":37},"+45 66113333",{"facility":116,"status":78,"city":117,"state":118,"zip":119,"country":120,"countryCode":121,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Evangelismos General Hospital of Athens ( Site 5100)","Athens","Attica","106 76","Greece","GR",{"type":85,"coordinates":123},[124,125],23.72784,37.98376,{"lat":125,"lon":124},[128],{"name":92,"role":72,"phone":129,"phoneExt":37,"email":37},"00302132041",{"facility":131,"status":78,"city":117,"state":118,"zip":132,"country":120,"countryCode":121,"cosmosGeoPoint":133,"geoPoint":135,"contacts":136},"General Hospital of Athens \"Laiko\" ( Site 5101)","115 27",{"type":85,"coordinates":134},[124,125],{"lat":125,"lon":124},[137],{"name":92,"role":72,"phone":138,"phoneExt":37,"email":37},"+302132061702",{"facility":140,"status":78,"city":141,"state":37,"zip":142,"country":120,"countryCode":121,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"University Hospital of Ioannina ( Site 5103)","Ioannina","455 00",{"type":85,"coordinates":144},[145,146],20.85187,39.66341,{"lat":146,"lon":145},[149],{"name":92,"role":72,"phone":150,"phoneExt":37,"email":37},"+302651099656",{"facility":152,"status":78,"city":153,"state":37,"zip":154,"country":155,"countryCode":156,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"Rambam Health Care Campus ( Site 0903)","Haifa","3109601","Israel","IL",{"type":85,"coordinates":158},[159,160],34.99928,32.81303,{"lat":160,"lon":159},[163],{"name":92,"role":72,"phone":164,"phoneExt":37,"email":37},"+97247772547",{"facility":166,"status":78,"city":167,"state":37,"zip":168,"country":155,"countryCode":156,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Haddasah Medical Center ( Site 0900)","Jerusalem","9112001",{"type":85,"coordinates":170},[171,172],35.21633,31.76904,{"lat":172,"lon":171},[175],{"name":92,"role":72,"phone":176,"phoneExt":37,"email":37},"97226777333",{"facility":178,"status":78,"city":179,"state":37,"zip":180,"country":155,"countryCode":156,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Sheba Medical Center ( Site 0902)","Ramat Gan","5265601",{"type":85,"coordinates":182},[183,184],34.81065,32.08227,{"lat":184,"lon":183},[187],{"name":92,"role":72,"phone":188,"phoneExt":37,"email":37},"+97235308401",{"facility":190,"status":78,"city":191,"state":37,"zip":192,"country":155,"countryCode":156,"cosmosGeoPoint":193,"geoPoint":197,"contacts":198},"Sourasky Medical Center. ( Site 0904)","Tel Aviv","6423906",{"type":85,"coordinates":194},[195,196],34.78057,32.08088,{"lat":196,"lon":195},[199],{"name":92,"role":72,"phone":200,"phoneExt":37,"email":37},"+97237772647",{"facility":202,"status":78,"city":203,"state":204,"zip":205,"country":206,"countryCode":207,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"Policlinico Universitario Agostino Gemelli ( Site 1003)","Rome","Roma","00168","Italy","IT",{"type":85,"coordinates":209},[210,211],12.51133,41.89193,{"lat":211,"lon":210},[214],{"name":92,"role":72,"phone":215,"phoneExt":37,"email":37},"00390630154968",{"facility":217,"status":78,"city":218,"state":219,"zip":220,"country":221,"countryCode":222,"cosmosGeoPoint":37,"geoPoint":37,"contacts":223},"Tokyo Metropolitan Komagome Hospital ( Site 2106)","Bunkyo","Tokyo","113-8677","Japan","JP",[224],{"name":92,"role":72,"phone":225,"phoneExt":37,"email":37},"+81-3-3823-2101",{"facility":227,"status":78,"city":228,"state":219,"zip":229,"country":221,"countryCode":222,"cosmosGeoPoint":230,"geoPoint":234,"contacts":235},"Toranomon Hospital ( Site 2101)","Minato","105-8470",{"type":85,"coordinates":231},[232,233],139.7515,35.6581,{"lat":233,"lon":232},[236],{"name":92,"role":72,"phone":237,"phoneExt":37,"email":37},"+81-3-3588-1111",{"facility":239,"status":78,"city":240,"state":241,"zip":242,"country":243,"countryCode":244,"cosmosGeoPoint":37,"geoPoint":37,"contacts":245},"Radboud UMC ( Site 2003)","Geert Grooteplein-Zuid 8","Gelderland","6500 HB","Netherlands","NL",[246],{"name":92,"role":72,"phone":247,"phoneExt":37,"email":37},"0243618800",{"facility":249,"status":78,"city":250,"state":251,"zip":252,"country":243,"countryCode":244,"cosmosGeoPoint":253,"geoPoint":257,"contacts":258},"Amsterdam UMC ( Site 2001)","Amsterdam","North Holland","1081 HV",{"type":85,"coordinates":254},[255,256],4.88969,52.37403,{"lat":256,"lon":255},[259],{"name":92,"role":72,"phone":260,"phoneExt":37,"email":37},"+31204443628",{"facility":262,"status":78,"city":263,"state":264,"zip":265,"country":266,"countryCode":267,"cosmosGeoPoint":268,"geoPoint":272,"contacts":273},"Institut Català d'Oncologia (ICO) - Badalona ( Site 3001)","Badalona","Barcelona","08916","Spain","ES",{"type":85,"coordinates":269},[270,271],2.24741,41.45004,{"lat":271,"lon":270},[274],{"name":92,"role":72,"phone":275,"phoneExt":37,"email":37},"+34934978387",{"facility":277,"status":78,"city":278,"state":37,"zip":279,"country":266,"countryCode":267,"cosmosGeoPoint":280,"geoPoint":284,"contacts":285},"HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 3009)","Madrid","28233",{"type":85,"coordinates":281},[282,283],-3.70256,40.4165,{"lat":283,"lon":282},[286],{"name":92,"role":72,"phone":287,"phoneExt":37,"email":37},"+34914521900",{"facility":289,"status":78,"city":290,"state":37,"zip":291,"country":266,"countryCode":267,"cosmosGeoPoint":292,"geoPoint":296,"contacts":297},"Hospital Universitario de Salamanca ( Site 3002)","Salamanca","37007",{"type":85,"coordinates":293},[294,295],-5.66388,40.96882,{"lat":295,"lon":294},[298],{"name":92,"role":72,"phone":299,"phoneExt":37,"email":37},"+34923291100",{"type":301,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100636783","phase-2-a-clinical-trial-of-mk-1045-in-people-with-b-cell-acute-lymphoblastic-leukemia-mk-1045-005-100636783",false,"NCT07570173","A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)","A Phase 2\u002F3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)","Inclusion Criteria:\n\n* Has a confirmed diagnosis of relapsed\u002Frefractory (R\u002FR) B-precursor acute lymphoblastic leukemia (ALL) with 5% or more lymphoblasts in the bone marrow\n* Has CD19+ disease, confirmed by local flow cytometry and\u002For immunohistochemistry testing at the time of enrollment\n* Has Philadelphia-negative disease, confirmed by testing, at the time of enrollment\n* Participants who have AEs due to previous anticancer therapies must have recovered to Grade ≤1 or baseline\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy (ART)\n\nExclusion Criteria:\n\n* Has Burkitt's leukemia\n* History or presence of clinically relevant central nervous system (CNS) diseases such as epilepsy, hemorrhagic\u002Fischemic stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, and psychosis\n* Has active acute graft versus host disease (GvHD) or chronic GvHD. NOTE: Participants who have received CNI for GvHD within 4 weeks before the first dose of study intervention are also excluded\n* History of serious cardiovascular and cerebrovascular diseases.\n* HIV-infection with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Received prior treatment with blinatumomab within 12 weeks for Part 1 and 24 weeks for Part 2 before the first dose of study intervention (individuals known to be refractory or intolerant to blinatumomab are to be excluded). Refractory to blinatumomab is defined as failure to achieve a response after at least 2 cycles of previous blinatumomab treatment\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Isolated extramedullary disease (EMD)\n* Active autoimmune disease unrelated to ALL that has required systemic treatment in the past 2 years or history of autoimmune disease with potential CNS involvement\n* Active infection requiring systemic therapy\n* Has not adequately recovered from major surgery or have ongoing surgical complications","ALL","12 Years",{"count":312,"type":313},340,"ESTIMATED","INTERVENTIONAL",[316,317],"PHASE2","PHASE3","Researchers are looking for new ways to treat people with relapsed or refractory B-cell acute lymphoblastic leukemia (R\u002FR B-ALL) that is CD19 positive using a medicine called MK-1045. MK-1045 is an immunotherapy, which is a treatment that helps the immune system fight cancer. This trial will compare MK-1045 to a standard immunotherapy called blinatumomab. The goals of this trial are to learn if more people who receive MK-1045 have no cancer cells in their bone marrow compared to people who receive blinatumomab and if people who receive MK-1045 live longer compared to people who receive blinatumomab.",[320],"B-cell Acute Lymphoblastic Leukemia","2026-08-13",{"date":323,"type":324},"2026-08-14","ACTUAL",{"date":326,"type":324},"2026-05-18",{"date":328,"type":313},"2033-10-18",{"name":5,"class":6},18]